Near-infrared light triggered activation of pro-drug combination cancer therapy and induction of immunogenic cell death
- Xuejia Kang,
- Yuxin Cai,
- Qi Wang,
- Chuanyu Wang,
- Wu Chen,
- Wen Yang
- Auburn University,
Open access
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
Disulfiram copper complex [Cu(DDC)2] nanoparticles have been explored as promising anticancer agents but with concerns of toxic side effects. To improve tumor specificity and enhance anticancer efficacy, we developed a novel [copper sulfide nanoparticle (CuS NP) + disulfiram prodrug (DQ) micelle + near-infrared (NIR) laser] (CDL) combination therapy. DQ, a reactive oxygen species (ROS)-responsive prodrug, can be selectively activated at the tumor site with elevated ROS to release DDC and form Cu(DDC)2 in situ. The CuS NP + NIR laser treatment can effectively increase the intra-tumor ROS levels and efficiently activate the DQ prodrug. The CDL therapy kills cancer cells through multiple mechanisms, including ROS amplification cascade and Cu(DDC)2 chemotherapy. NIR light-triggered tumor-specific “nontoxic-to-toxic” transition can significantly improve the specificity of anticancer effects and reduce systemic toxicity. Also, CDL therapy can effectively induce immunogenic cell death (ICD) and has the potential of eliciting antitumor immunity.
Publication Information
Output type
Original language
English (US)Article number
120972Journal (Volume, Issue Number)
International Journal of Pharmaceutics (Volume 607)Publication milestones
- Published - 09/25/2021
Publication status
ISSN
0378-5173Publication IDs
- Scopus: 85113205208
- PubMed: 34363916
